Platinum-Based Drugs in Cancer Therapy

by Kelland, Lloyd R.; Farrell, Nicholas

• ISBN13: 9780896035997
• ISBN10: 0896035999
• Format: Hardcover
• Copyright: 2000-03-01
• Publisher: Humana Pr Inc

Summary

Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.

Table of Contents

Preface	v
Contributors	xi
Part I: Platinum Chemistry
The Chemistry of Cisplatin in Aqueous Solution	3	(34)
Susan J. Berners-Price
Trevor G. Appleton
Chemistry and Structural Biology of 1,2-Interstrand Adducts of Cisplatin	37	(26)
Viktor Brabec
Transplatin-Modified Oligonucleotides as Potential Antitumor Drugs	63	(26)
Marc Leng
Annie Schwartz
Marie-Josephe Giraud-Panis
Part II: Platinum Biochemistry
Cisplatin Accumulation	89	(26)
Paul A. Andrews
Cisplatin Resistance in Ovarian Cancer: Mismatch Repair and Engagement of Apoptosis	115	(14)
Robert Brown
DNA Adduct Tolerance and Bypass	129	(20)
Stephen G. Chaney
Alexandra Vaisman
How Does Cisplatin Kill Cells?	149	(22)
Daniel Fink
Stephen B. Howell
Part III: Clinical Antitumor Activity and Toxicology of Platinum Drugs
Clinical Experience with Cisplatin and Carboplatin	171	(24)
Martin S. Highley
A. Hilary Calvert
Clinical Experience: Platinum and Taxanes	195	(36)
Michelle Vaughan
Francisco Sapunar
Martin Gore
Clinical Experience: DACH-Based Platinum Drugs	231	(20)
Peter J. O'Dwyer
James P. Stevenson
Steven W. Johnson
Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents	251	(26)
Mark J. McKeage
Toxicology and Regulatory Aspects of Platinum Drugs	277	(22)
Diana L. Clark
Paul A. Andrews
D. D. Smith
Joseph J. DeGeorge
Robert L. Justice
Julie G. Beitz
Part IV: New Platinum Drugs of the Future
New Platinum Drugs: The Pathway to Oral Therapy	299	(22)
Lloyd R. Kelland
Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm	321	(18)
Nicholas Farrell
Index	339